Psychosis; Episode Clinical Trial
— PLAN-e-PSYOfficial title:
A Mobile Application to Improve Case-management and Patient's Functioning in First Episode Psychosis : an Open-label, Multicentre, Superiority, Randomised Controlled Trial Study
First Episode Psychosis (FEP) includes perceptual distortions, delusions and cognitive impairment with severe consequences, such as suicidal behaviour. It affects 3% of the population, mainly adolescents and young adults, the majority of with progress to a psychotic disorder. The early stages of psychotic disorders, from the first full blown symptoms to the next two to five years, represent an opportunity to targeted care and prevention. Indeed, it is a critical period with a worsened clinical prognostic when intervention is delayed, increasing the duration of untreated psychosis (DUP). Also, it is a key period to reduce mortality, as it is characterized by elevated risks of suicide and low physical health outcomes. Besides the symptomatic components, this period is also critical for self-building on educational, professional and emotional levels. Early intervention programmes involve multi-disciplinary teams, including a care coordination function, embodied by a "case manager". His missions include assessing the patient's needs, developing a care plan to meet the latter, organising access to the different components of the care plan, monitoring and evaluating care, and providing clinical follow-up. Engagement in the care process is fragile in psychotic disorders, particularly in the context of first episode psychosis with a high risk of care disengagement, often associated with a relapse. It is therefore essential that case-managers involved in FEP services have access to tools designed according to the patient needs and not solely to symptoms, in a "recovery oriented" approach, to foster the feeling of commitment of patients in their care process. The use of mobile applications for smartphones represents an interesting perspective to improve the engagement of patients with FEP in care. However, the use of an application focused on recovery is feasible and acceptable in patients with first episode psychosis enrolled in a specialised outpatient department (FEP-type service) and allows improvement on clinical criteria, such as psychotic symptoms or mood. User-centred design methods including identification of users and an inventory of their needs, prototyping with rapid iterations, is a simplification of the procedure and exploitation of existing constraints to increase the rate of use. Moreover, it has recently been shown that such a methodology is feasible in populations with a first episode of psychosis. Our hypothesis is that the use of a mobile case-management application for planning and monitoring individualised care objectives, co-designed with patients, their careers, and health professionals, improves the functioning of patients managed for a first psychotic episode, compared to usual case management practices. The originality of our project is built up on two pillars : - the use of a a mobile monitoring application, which will be used jointly by patients and case-managers, - the methodological innovation also lies in the collaborative and patient-centred design of the application The originality of our project concerns on the one hand the intervention, an application mobile follow-up, which will be used jointly by patients and case managers. The innovative character also lies at the methodological level in the collaborative and patient-centered design of the application ('user-centered design' approach).
Status | Not yet recruiting |
Enrollment | 168 |
Est. completion date | January 4, 2025 |
Est. primary completion date | January 4, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion Criteria: - Men and women aged between 18 and 30 years old enrolled in a specialised FEP service for a first psychotic episode, defined as follows: Presence of daily psychotic symptoms for more than a week that have been characterised at the clinical examination by a psychiatrist, Initiation of antipsychotic treatment for less than 6 months, A diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder or brief psychotic disorder established according to DSM-5 criteria. - Mastery of the French language (read and spoken) - Owning a smartphone - Adult patients who have given written consent Exclusion Criteria: - Patients in psychiatric intensive care units because of severe agitation/disorganisation. - Patients under guardianship |
Country | Name | City | State |
---|---|---|---|
France | Ch Le Vinatier | Lyon | Rhone Alpes |
Lead Sponsor | Collaborator |
---|---|
Hôpital le Vinatier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Personal and Social Performance (PSP) scale | Variation in the patient's functioning score measured by the "Personal and Social Performance (PSP)" scale, informed by a psychiatrist, trained in the use of the scale, not directly involved in the patient's follow-up and blinded to the patient's randomisation group.
This hetero-evaluative scale, available in French, assesses functioning in a single score that takes into account four domains: productive social activities (work/study), social network, personal care, and disruptive or aggressive behaviour. The integrative score ranges from 0 to 100, with higher scores reflecting better functioning. Functioning corresponds to an individual's capacity to assume his or her social role, in the domestic, professional or school, emotional, family and friendship spheres. This is the final objective of case-managed FEPs. |
Between inclusion and 12 months | |
Secondary | Evolution of the Personal and Social Performance Scale PSP | Evolution of the functioning score measured by the PSP in the patient. The outcome will be the evolution of the PSP score compared in both groups. Total score range: 1 to 100, higher score indicates better functioning. | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Therapeutic alliance | Therapeutic alliance as measured by the working alliance inventory (WAI) ): total score range: 36 to 252, higher score indicates better working alliance, patient scale and caregiver scale (case-manager). The outcome will be the evolution of the WAI score compared in both groups. | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Adherence to drug treatment | Adherence to drug treatment as measured by the Medical Adherence Rating Scale (MARS) score total score range: 0 to 10, higher score indicates better medical adherence. The assessment criterion will be the evolution of the MARS score compared in both groups. | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Psychotic symptomatology | Psychotic symptomatology assessed by the Positive and Negative Symptoms Scale (PANSS) : total score range: 30 to 210, higher score indicates worse symptomatology. This questionnaire hetero assessment gives 3 scores, positive symptoms, negative symptoms and general psychopathology. The outcome will be the evolution of the PANSS score compared in both groups | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Recovery | Recovery assessed by the Stages of Recovery Instrument (STORI) the scale is composed of 50 items, grouped in 10 categories. Each categories represents one of the four process components of recovery: hope; identity; meaning; responsibility. The assessment criterion will be the evolution of the STORI score compared in both groups | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Life self-report scale | Quality of life assessed by the Schizophrenia Quality of Life self-report scale - 18 items (S-QoL-18) : the scale is composed of 18 items regrouped in 8 dimensions ranging from 0 to 100. A total score is also calculated (range 0-100). Lower scores indicate lower quality of life. The outcome will be the evolution of the S-QoL-18 score compared in both groups | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Level of empowerment | Level of empowerment assessed by the Patient Activation Measure (PAM) self-questionnaire (total score range: 0 to 100, higher score indicates higher activation level). The evaluation criterion will be the evolution of the PAM score compared in both groups. | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Patient engagement in care | Patient engagement in care assessed by the Service Engagement Scale (SES) translated into French (: total score range: 0 to 42. Higher scores reflected clients' greater levels of difficulty engaging with services). The evaluation criterion will be the evolution of the SES score compared in both groups. | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Patient satisfaction with case-management | Patient satisfaction with case-management assessed by a self-administered questionnaire constructed in the study using a visual analogue scale (VAS). The evaluation criterion will be the evolution of the VAS score compared in the centre and both groups | Between inclusion and 6 months and between inclusion and 12 months | |
Secondary | Hospitalisation for relapse of psychosis | Evaluation in the patient in both groups of the number of days of hospitalisation for relapse of psychosis, collected at follow-up. | Over12 months | |
Secondary | Acceptability and appropriation of the PLAN-e-PSY application | The acceptability and appropriation of the application (intervention group) by patients (strengths and limitations of the application) and the case-manager (strengths and limitations of the application, perceived change in practices, commitment) assessed during the semi-structured interviews | At 12 months | |
Secondary | Fidelity of use of the PLAN-e-PSY application | Fidelity of use by the case manager and patients of the different parts of the application in relation to the defined procedures. These elements will be collected from the application's internal monitoring data | Over12 months | |
Secondary | Case manager effective use of the PLAN-e-PSY application | Proportion of case manager consultations during which the application was not used. These elements will be collected from the application's internal monitoring data | At 12 months | |
Secondary | Patient effective use of the PLAN-e-PSY application | Proportion of patients who stopped using the application. These elements will be collected from the application's internal monitoring data | At 12 months | |
Secondary | Time of effective use of the PLAN-e-PSY application | Time of effective use by the case manager and patients of the application. These elements will be collected from the application's internal monitoring data | Over 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04429412 -
Effectiveness of the Individualized Metacognitive Training (EMC+) in People With Psychosis of Brief Evolution
|
N/A |